http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005054560-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f84747e8d08b1023763356d0e7d1db68 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70585 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2002-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcb3c7d5b47208f0cf3b81190de0a223 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33f85dfa29850b5985bc23502013d7ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eedc9f0f3b48183444dfab346a91bc8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0ae99341d5cce5a73352d8d541be6f8 |
| publicationDate | 2005-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005054560-A1 |
| titleOfInvention | Cd44 variants carrying heparan sulfate chains and uses thereof |
| abstract | Modulation of the activity of a heparin-binding growth factor (HBGF) by enhancing or inhibiting high affinity binding of said HBGF to its receptor, can be achieved with an agent selected from: (i) a soluble CD44 isoform carrying at least one chain of a heparan sulfate; (ii) a recombinant chimeric fusion protein comprising the amino acid sequence of a soluble CD44 isoform fused to a tag suitable for proteoglycan purification, said fusion molecule being post-translationally glycosylated to carry at least one chain of a heparan sulfate; and (iii) a sugar molecule being a heparan sulfate derived from a CD44 isoform, or a fragment thereof. The agents (i) and (ii) when the soluble CD44 isoform is the soluble CD44 variant expressed in synovial cells of rheumatoid arthritis patients (CD44vRA), and the heparan sulfate of (iii), are novel. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9694072-B2 |
| priorityDate | 2001-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 472.